RT Conference Proceedings
T1 THE ANALYSIS OF THE INFLAMMATORY PROTEOME IN RHEUMATOID ARTHRITIS IDENTIFIES COMMON SIGNATURES ASSOCIATED WITH THE CLINICAL RESPONSE TO DMARDS AND TNFI THERAPIES
A1 Munoz-Barrera, L.
A1 Perez-Sanchez, C.
A1 Contreras, A. Escudero
A1 Aguirre-Zamorano, M. A.
A1 Gutierrez, J. Calvo
A1 Castro, R. Ortega
A1 Romero-Gomez, M.
A1 Sanchez-Pareja, I.
A1 Abalos-Aguilera, M. C.
A1 Puerto, N. Barbarroja
A1 Venegas, J. J. Perez
A1 Ruiz-Montesinos, D.
A1 Rodriguez-Escalera, C.
A1 Romero-Barco, C. M.
A1 Mena-Vazquez, N.
A1 Fernandez-Nebro, A.
A1 Uceda, J.
A1 Marenco, J. L.
A1 Estevez, E. Collantes
A1 Lopez-Pedreraon, C.
AB Background: The clinical outcome of the most common therapeutic options of rheumatoid arthritis (RA) patients, such as conventional disease-modifying antirheumatic drugs (DMARDs) and TNF inhibitors (TNFi) is still unpredictable, since a high percentage of patients do not response to the therapy. Innovative analyses combining high-throughput technologies and thorough clinical assessments are needed to gain insight about the management of this prevalent autoimmune disorder.
PB BMJ Group
SN 0003-4967
YR 2022
FD 2022-06-01
LK http://hdl.handle.net/10668/20117
UL http://hdl.handle.net/10668/20117
LA en
NO Muñoz-Barrera L, Perez-Sanchez C, Contreras AE, Aguirre-Zamorano MÁ, Gutierrez JC, Castro RO, et al. POS0440 THE ANALYSIS OF THE INFLAMMATORY PROTEOME IN RHEUMATOID ARTHRITIS IDENTIFIES COMMON SIGNATURES ASSOCIATED WITH THE CLINICAL RESPONSE TO DMARDs AND TNFI THERAPIES. Annals Of The Rheumatic Diseases [Internet]. 23 de mayo de 2022;81(Suppl 1):475.1-475
DS RISalud
RD Apr 9, 2025